Summit Corporation Plc (SUMM) Company Profile - CorporateInformation.com

Company Search:

Advanced Search

Wright Investors Service Perspectives


	The Wright Reports site is no longer hosted or operated by Manta. Please review the following: 1. You have been redirected to CorporateInformation.com where you can view Snapshot reports or purchase Wright reports or subscriptions of your choosing. 2. If you were previously linking to Wright Reports please change your links to www.corporateinformation.com 3. If you are a paid subscriber with an active subscription please continue on to the member site: http://member.corporateinformation.com/home.asp 4. For additional information related to CorporateInformation.com please contact help@corporateinformation.com, Contact phone nr to be provided later)

Summit Corporation Plc Company Snapshot

Business Description:

Summit Corporation Plc operates in the Pharmaceutical preparations sector. Summit Corporation plc (Summit) is engaged in the discovery and development of new therapeutics from its Seglin technology drug discovery platform in areas of unmet medical need. The drug discovery segment covers Summit's licensing revenue business, all research and development activities carried out by it, including the drug discovery platform called Seglin technology, the non-Seglin drug programmes and any other discovery stage research. Summit's programmes include SMT 19969, SMT C1100, SMT C2100, SMT 14224, SMT 15000, SMT D001, SMT D002, Glaucoma and Tuberculosis Programme. Summit's pipeline consists of clinical, preclinical and discovery stage programmes and includes a number that have been developed from its Seglin technology. The Company's subsidiaries, include Summit (Oxford) Limited, Summit (Wales) Limited, Summit (Wales) Limited, Summit (Wales) Limited and Summit Corporation Employee Benefit. In our complete report available for purchase the company is compared to: Angel Biotechnology Holdings PLC, Ark Therapeutics Group Plc and 4SC Ag.

Summit Corporation Plc

Stock Performance Chart for Summit Corporation Plc

Stock Data:

Recent Stock Performance:

Current Price (2/3/2012): 6.50p
(Figures in Pounds Sterling)

1 Week	33.3%		13 Weeks	26.8%

4 Weeks	-7.1%		52 Weeks	188.9%

Summit Corporation Plc Key Data:

	Ticker:	SUMM	Country:	UNITED KINGDOM

	Exchanges:	LON	Major Industry:	Drugs, Cosmetics & Health Care

			Sub Industry:	Ethical Drug Manufacturers

	2011 Sales	763,000 (Year Ending Jan 2012).	Employees:	31

	Currency:	Pounds Sterling	Market Cap:	12,031,291

	Fiscal Yr Ends:	January	Shares Outstanding:	185,096,784

	Share Type:	Ordinary	Closely Held Shares:	63,932,134

Feedback | Terms and Conditions | Privacy Policy | Site Index

CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.